The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna (15–19 Sept) finds that half of adults without diabetes who start taking the weight-loss drug semaglutide in Denmark discontinue treatment within a year.
Go to Source
https://medicalxpress.com/rss-feed/